CCR2 and central nervous system cancer: Conversely, there was a significant reduction (p=0.003) from mean 25.8% to mean 10.8% glioma infiltrating CCR2+/CX3CR1+ cells when comparing KR158B + IgG vs. CCL7 KD + αCCL2 antibody arms (Figures 6C, E).